Loading...
•
Dec 31, 2021
Design Therapeutics Q4 2021 Earnings Report
Reported pipeline and business progress and fourth quarter and full year 2021 financial results.
Key Takeaways
Design Therapeutics reported its Q4 and full year 2021 financial results, highlighting the clearance of the IND for DT-216 and progress in developing GeneTACTM molecules for myotonic dystrophy type-1 and Fuchs endothelial corneal dystrophy. The company ended the year well-capitalized with $384.1 million in cash and investments.
IND Application for FA Development Candidate, DT-216, Cleared by the FDA.
Preclinical Data Highlighting Novel GeneTAC™ Therapy for the Treatment of FECD to be Presented at ARVO 2022.
Strengthened Leadership Team with Appointment of Chief Medical Officer.
Cash, cash equivalents and marketable securities were $384.1 million as of December 31, 2021.
Forward Guidance
Statements in this press release that are not purely historical in nature are "forward-looking statements".
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...